Lõuna-Aafrika Vabariik - inglise - South African Health Products Regulatory Authority (SAHPRA)

organon south africa (pty) ltd - tablet - see ingredients - each tablet contains rizatriptan benzoate equivalent to rizatriptan 5 mg

Lõuna-Aafrika Vabariik - inglise - South African Health Products Regulatory Authority (SAHPRA)

organon south africa (pty) ltd - tablet - see ingredients - each tablet contains rizatriptan benzoate equivalent to rizatriptan 10 mg

Lõuna-Aafrika Vabariik - inglise - South African Health Products Regulatory Authority (SAHPRA)

organon south africa (pty) ltd - wafer - see ingredients - each wafer contains rizatriptan benzoate equivalent to rizatriptan 5 mg

Lõuna-Aafrika Vabariik - inglise - South African Health Products Regulatory Authority (SAHPRA)

organon south africa (pty) ltd - wafer - see ingredients - each wafer contains rizatriptan benzoate equivalent to rizatriptan 10 mg

Lõuna-Aafrika Vabariik - inglise - South African Health Products Regulatory Authority (SAHPRA)

organon south africa (pty) ltd - tablet - see ingredients - each tablet contains hydrochlorothiazide 25,0 mg losartan potassium 100,0 mg

Lõuna-Aafrika Vabariik - inglise - South African Health Products Regulatory Authority (SAHPRA)

organon south africa (pty) ltd - tablet - see ingredients - each tablet contains montelukast sodium equivalent to montelukast 4,0 mg

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

moberg pharma north america llc - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - acetaminophen 194 mg

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

csl behring llc - antihemophilic factor, human recombinant (unii: p89dr4ny54) (antihemophilic factor, human recombinant - unii:p89dr4ny54) - antihemophilic factor, human recombinant 250 [iu] in 2.5 ml - helixate® fs is a recombinant antihemophilic factor indicated for: helixate fs is not indicated for the treatment of von willebrand disease. helixate fs is contraindicated in patients who have life-threatening hypersensitivity reactions, including anaphylaxis to mouse or hamster protein or other constituents of the product (sucrose, glycine, histidine, sodium, calcium chloride, polysorbate 80, imidazole, tri-n-butyl phosphate, and copper). pregnancy category c animal reproduction studies have not been conducted with helixate fs. it is also not known whether helixate fs can cause fetal harm when administered to a pregnant woman or affect reproductive capacity. helixate fs should be given to a pregnant woman only if clearly needed. there is no information available on the effect of factor viii replacement therapy on labor and delivery. helixate fs should be used only if clinically needed. it is not known whether this drug is excreted into human milk. because many drugs are excreted into human milk, caution sho

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

precision nuclear llc - ammonia n-13 (unii: 9oqo0e343z) (ammonia n-13 - unii:9oqo0e343z) - ammonia n-13 260 mci in 1 ml - ammonia n 13 injection usp is indicated for diagnostic positron emission tomography (pet) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. none pregnancy category c animal reproduction studies have not been conducted with ammonia n 13 injection. it is also not known whether ammonia n 13 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ammonia n 13 injection should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk and because of the potential for radiation exposure to nursing infants from ammonia n 13 injection, use alternative infant nutrition sources (e.g., stored breast milk or infant formula) for 2 hours (> 10 half-lives of radioactive decay for n 13 isotope) after administration of the drug or avoid use of the drug, taking